



Lipomics Receives Department of Defense Grant for Study Using Lipid Analysis to Assess Fitness

Study results to help develop blood-based diagnostic profiles to predict fitness and endurance of combat personnel

WEST SACRAMENTO, Calif., September 13, 2006 -- Lipomics Technologies, Inc., a privately held company that specializes in lipid metabolite analysis and interpretation, today announced that it has been competitively selected to receive a Phase II Small Business Technology Transfer Grant from the Department of Defense to improve the optimum fitness and performance of combat personnel. The study findings will be used to develop diagnostic tools that will evaluate an individual soldier's readiness for training and predict the potential for injury during times of physical stress. The study findings will also be evaluated for their diagnostic potential in physical fitness programs of the general population.

Collaborating with the University of California, Davis, and Arête Therapeutics, Inc., Phase I of the study, conducted last year, employed validated metabolomic analysis platforms to determine how metabolic profiles can predict performance, metabolic stress, fatigue, and recovery rates for individuals undergoing extreme exertion. Phase II and III of this study will be performed by Dr. Patricia Deuster at the Uniformed Services University of Health Science.

“An objective measure of our war-fighters' physical and psychological wellbeing will promote optimal military performance, avoid the deleterious consequences of fatigue, and potentially reduce the risk of injury,” said Dr. Deuster.

Lipomics will be applying its years of accumulated knowledge in evaluating metabolic response to produce a practical, personalized diagnostic test that will help improve training regimens, dietary guidance and if necessary, therapeutic interventions to optimize their preparedness prior to and recovery after exhaustive activity. The development of this test will advance Lipomics' strategic vision of creating a suite of commercially available diagnostic assays based on metabolic profiles for health, fitness and disease.

About Lipomics Technologies, Inc.

Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolism analysis and data interpretation. We generate a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to

speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. More information about Lipomics can be found at www.lipomics.com.

#

EDITORIAL CONTACTS:

Sarina Chohan
(916) 371-7974
schohan@lipomics.com

Agency Contact

Doug Forsyth, Alchymia Communications
(541) 482-8744
df@alchymiacomm.com